miércoles, 3 de enero de 2018

Melanoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Melanoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute



National Cancer Institute

Melanoma Treatment (PDQ®)–Health Professional Version



SECTIONS



Changes to This Summary (12/21/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Editorial changes were made to this section.
Updated staging information for 2016 (cited American Joint Committee on Cancer as reference 1).
This section was extensively revised.
Added a list item about an assessment of a change in the dosing regimen for nivolumab in metastatic melanoma (cited Zhao et al. as reference 5).
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: December 21, 2017

No hay comentarios:

Publicar un comentario